To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Oxygen Biotherapeutics Announces Plans for Additional Oxycyte® Phase II Clinical Trials
Read time: Less than a minute
Oxygen Biotherapeutics, Inc. has announced plans to file a Phase II, dose escalation, clinical trial protocol in Switzerland for use of Oxycyte® in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.
The announcement came in a presentation by Chris J. Stern, DBA, company chairman and CEO, at the BIO CEO & Investor Conference in New York. During the presentation, Stern said that the company is in the final stages of preparation to file the protocol in Switzerland. “Depending on the timing of the review process there, we could begin enrolling patients in the second quarter,” said Stern.
In addition, Stern said in the presentation that the company is targeting to have a topical wound care product ready to come to market as early as the end of 2009.
The announcement came in a presentation by Chris J. Stern, DBA, company chairman and CEO, at the BIO CEO & Investor Conference in New York. During the presentation, Stern said that the company is in the final stages of preparation to file the protocol in Switzerland. “Depending on the timing of the review process there, we could begin enrolling patients in the second quarter,” said Stern.
In addition, Stern said in the presentation that the company is targeting to have a topical wound care product ready to come to market as early as the end of 2009.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
